How to Evaluate Emerging and Experimental Therapies
A practical framework for evaluating new and experimental mental health treatments — from psychedelic-assisted therapy to digital platforms — so you can separate genuine innovation from hype.
When "New" Does Not Mean "Better" (or "Worse")
A headline announces a breakthrough therapy. A podcast guest describes a single psychedelic session that resolved years of treatment-resistant depression. A friend swears by a new digital platform that "replaced" their therapist. It is easy to feel excited — and just as easy to feel skeptical.
Both reactions make sense, and both can lead you astray. Novelty bias — the tendency to assume that newer automatically means better — can push people toward treatments that have not been adequately tested. But reflexive dismissal is equally unhelpful. Every therapy that is now considered a gold standard, including CBT and EMDR, was once the new, unproven idea that skeptics questioned.
The goal is not to be a cheerleader or a cynic. It is to think clearly. This guide gives you a practical framework for evaluating emerging therapies so you can make informed decisions about your care — or at least ask the right questions.
130+
The Path From Lab to Practice
Understanding how therapies move from idea to established treatment helps you gauge where a new approach actually stands. The process differs depending on whether a therapy involves a drug or is purely psychological, but both follow a general pattern of increasingly rigorous testing.
Drug-Assisted Therapies (e.g., Psilocybin, MDMA, Ketamine)
Drug-based treatments must go through a formal regulatory pipeline before they can be prescribed:
- Preclinical research: Laboratory and animal studies establish basic safety and potential mechanisms
- Phase 1 trials: Small studies with healthy volunteers test safety and dosing
- Phase 2 trials: Larger studies with patients who have the target condition test effectiveness and refine dosing
- Phase 3 trials: Large-scale, multi-site randomized controlled trials compare the drug to a placebo or existing treatment
- FDA review and approval: The FDA evaluates the full body of evidence and decides whether to approve the drug for clinical use
This process typically takes 10 to 15 years and costs hundreds of millions of dollars. An approach in Phase 2 is promising but far from proven. An approach in Phase 3 is much closer but still not guaranteed.
Regulatory paths differ globally. The European Medicines Agency (EMA), Australia's Therapeutic Goods Administration (TGA), and other bodies operate on their own timelines — a treatment approved in one country may not yet be available in another.
Talk Therapies and Behavioral Interventions
Psychological therapies do not require FDA approval, but they follow their own evidence-building progression:
- Case studies and clinical observation: Therapists document outcomes with individual clients
- Pilot studies: Small, often uncontrolled studies test whether the approach is feasible and shows initial promise
- Randomized controlled trials (RCTs): The therapy is compared to a control condition (waitlist, treatment as usual, or another active therapy) with participants randomly assigned to each group
- Replication and meta-analyses: Independent researchers repeat the studies, and systematic reviews pool the results
- Practice guideline recognition: Organizations like the APA or NICE include the therapy in official clinical recommendations
- Dissemination: Training programs are developed, and the therapy becomes widely available
A therapy with one positive pilot study is in a very different place than one with multiple RCTs and guideline recognition. Both may be worth paying attention to, but they warrant different levels of confidence.
Emerging Therapies Worth Watching
Several new and developing treatments are generating significant research interest. Here is a brief evidence snapshot — not a deep dive, but enough to orient you. For detailed exploration, follow the links to our in-depth articles.
Psilocybin-assisted therapy has shown striking results in clinical trials for treatment-resistant depression and end-of-life distress. Multiple Phase 2 trials have been completed, and Phase 3 trials are underway. It is not yet FDA-approved and remains a Schedule I substance in most jurisdictions.
MDMA-assisted therapy was specifically developed as a treatment for PTSD. Phase 3 trials showed significant improvement, though the FDA declined initial approval in 2024 and requested additional data. The research continues, and revised submissions are expected.
Ketamine and esketamine represent the furthest along of the psychedelic-adjacent treatments. Esketamine (Spravato) received FDA approval in 2019 for treatment-resistant depression. IV ketamine is used off-label at specialized clinics, though long-term data are still limited.
Virtual reality exposure therapy (VRET) uses immersive VR environments to conduct exposure therapy for phobias, PTSD, and social anxiety. Multiple RCTs show it is comparable to traditional in-vivo exposure for specific phobias, with growing evidence for PTSD applications.
Digital CBT platforms deliver structured cognitive behavioral therapy through apps and web platforms, sometimes with therapist support and sometimes fully automated. Evidence is strong for mild to moderate depression and anxiety, though outcomes vary widely by platform and level of human involvement.
Emerging Therapies at a Glance
| Therapy | Target Condition | Evidence Stage | Key Finding | Access Status | Typical Cost |
|---|---|---|---|---|---|
| Psilocybin-assisted therapy | Treatment-resistant depression | Phase 2/3 trials | 50–70% response rates in trials | Clinical trials only | $1,500–$3,500 per session (estimated) |
| MDMA-assisted therapy | PTSD | Phase 3 (additional data requested) | 67% no longer met PTSD criteria post-treatment | Clinical trials only | $3,000–$5,000 per treatment course |
| Esketamine (Spravato) | Treatment-resistant depression | FDA-approved (2019) | Significant improvement vs. placebo in RCTs | Certified clinics (REMS program) | $600–$900 per session (may be covered) |
| VR exposure therapy | Phobias, PTSD, social anxiety | Multiple RCTs completed | Comparable to in-vivo exposure for phobias | Select specialty clinics | $150–$300 per session |
| Digital CBT platforms | Mild-moderate depression, anxiety | Strong (many RCTs) | Effect sizes similar to face-to-face CBT for mild cases | Widely available | $40–$120 per month |
Five Questions to Ask Before Trying an Emerging Therapy
Before pursuing any new or experimental treatment, work through these questions. They will not give you a definitive answer, but they will help you think more clearly and have a more productive conversation with your provider.
Clinical Trials: How to Participate Safely
If you are interested in an emerging therapy that is not yet widely available, participating in a clinical trial may be an option. Clinical trials are how new treatments get tested and eventually approved — and participants receive the treatment at no cost.
How to find trials. ClinicalTrials.gov is the primary registry for studies in the United States. You can search by condition, treatment type, and location. Many academic medical centers also list their active studies on their websites.
What informed consent means. Before enrolling, the research team is legally required to explain the study's purpose, procedures, risks, benefits, and your right to withdraw at any time. You will sign an informed consent document, and you should read it carefully — not just skim it.
What to expect. Clinical trials involve more monitoring than standard treatment. You may need to complete regular assessments, attend additional appointments, and follow specific protocols. Some trials use a placebo or control group, meaning you may not receive the experimental treatment.
Your rights as a participant. You can leave a clinical trial at any time, for any reason, without penalty. Your medical care will not be affected by your decision. Every trial involving human subjects must be approved by an Institutional Review Board (IRB), which exists to protect your safety and rights.
The Bottom Line
Emerging does not mean unproven, but it does mean less certain. The landscape of mental health treatment is evolving rapidly, and some of today's experimental therapies may become tomorrow's standard of care. Others will not survive rigorous testing.
Your job as an informed consumer is not to predict which therapies will make it. It is to ask good questions, understand what the evidence actually shows right now, and make decisions in partnership with a qualified provider. Be open to innovation. Be cautious about hype. And remember that the most important factor in any therapy — new or established — is whether it is delivered competently, ethically, and with your specific needs in mind.
For more on how to understand therapy research, see our guide to understanding therapy research and our overview of psychedelic-assisted therapy.
It depends on the specific therapy and how far along it is in the research process. Treatments in Phase 3 clinical trials have undergone significant safety testing. Treatments offered outside of clinical trials or regulatory oversight carry more uncertainty. Always ask about known risks, and be wary of any provider who claims there are none.
Psilocybin and MDMA are not FDA-approved and remain Schedule I substances in most of the United States. The primary legal way to access them is through a clinical trial. Some states and cities have decriminalized psilocybin, but decriminalization is not the same as clinical availability with trained support. Esketamine (Spravato) is FDA-approved and available through certified clinics.
Check that the provider holds a valid license in your state. Ask about their specific training in the emerging therapy and which organization provided it. Look for affiliation with a reputable institution or research program. Be cautious of providers who market unregulated treatments with promises of guaranteed results.
Off-label means a drug is FDA-approved for one condition but is being used for another based on clinical judgment and some supporting evidence. Experimental means the treatment is still being studied and has not yet received any FDA approval. IV ketamine for depression is an example of off-label use; psilocybin-assisted therapy is currently experimental.
If you have tried established, evidence-based treatments without sufficient improvement, exploring emerging options with your provider is reasonable. Treatment-resistant conditions are one of the primary reasons emerging therapies like ketamine and psilocybin are being studied. Work with your provider to evaluate whether a specific emerging therapy has enough evidence for your situation and what the risks are.
Exploring Your Treatment Options?
Whether you are considering an established therapy or an emerging approach, understanding the evidence is the first step. We can help you find a qualified provider.
Find a Therapist